Perjeta (pertuzumab) Disease area(s): Oncology Manufacturer(s): Roche 2024 Sales (USD): $4.11 billion Why it sold so well: Roches Perjeta generated global sales of CHF 3.62 billion ($4.11 billion) last year, maintaining its position as a key therapy in HER2-positive breast cancer
By dampening the overzealous cardiac response and providing a steadying hand to a racing heart, beta blockers may help patients reclaim a sense of normalcy and engage more fully in daily life activities
Yes, IGF-1 LR3 excels in promoting localized tissue repair, making it ideal for recovery after injuries
These formulations undergo the same quality and sterility standards as brand-name medications, manufactured in state-licensed facilities that meet FDA compliance requirements
All plaintiffs causation experts facing motions for exclusion will provide testimony, shaping the foundation of the case moving forward
Liraglutide or placebo was administered daily, starting at 0.6 mg and increasing to 3.0 mg or the highest tolerated dose